Seeking Alpha

Pannobhaso's  Instablog

Pannobhaso
Send Message
A researcher into gene silencing as a technology for improving the lives of those suffering from incurable diseases. Benitec Biopharma is my primary investment in this technology as ddRNAi offers one-time treatments for a broad range of these diseases.
  • Cash In The Bank 2 comments
    Feb 23, 2014 10:34 PM | about stocks: BNIKF, ARWR

    Benitec ($OTCPK:BNIKF) is about to raise up to AUD $31.5M in a share placement to institutional investors in the US and Australia. The placement price represents a 5.3% discount on the 15 day Volume Weighted Average as at February 21 2014. These 29.4M, AUD $1.07 shares will also attract options at an exercise price of AUD $1.26. If all the options are exercised, a further, additional 13.3 million ordinary shares will be added to the registry.

    This capital raising process seems to be following a similar pattern to Arrowhead Research ($ARWR) and if that is the case then investors can expect to see big returns. On April 30 2013 Arrowhead announced that it was raising USD $36M. On that day the share price closed at USD $2.06. On February 21 2014 the shares closed at USD $22.45, more than ten times the price at the time of the announcement. Arrowhead has a RNAi treatment for Hepatitis B (HBV) in a clinical trial and Benitec is to dose its first patient in a Hepatitis C (HCV) trial in the coming weeks. To this extent the companies are very similar and so it would not be unreasonable to assume that investor interest in Benitec may follow a similar pattern.

    Benitec also has a few other things going for it. Its licensee, Calimmune is already eight months into its clinical trial for HIV and positive results for this potential cure for HIV could have a dramatic effect on the value of Benitec. Two other licensees, Regen and Genable Technologies, have also announced that they expect to be in clinical trials in 2014. Benitec's ddRNAi technology is therefore advancing on a number of fronts.

    The new capital will be used to progress not only the HCV trial but also the development of treatments for Non-Small Cell Lung Cancer (NSCLC), Age-related Macular Degeneration (NYSE:AMD) and HBV. This is a particularly pleasing development as the current cash limit has meant that these programs have been on the backburner. NSCLC research has produced some very good pre-clinical results and should be in clinical trial before the end of the year. AMD is interesting because it represents the next generation of ddRNAi with the incorporation of miRNA. HBV will piggyback on the success of the HCV trial (liver is the same target) as much of the safety data will be the same and this should substantially decrease the time to market for the HBV treatment.

    I think this announcement is a very positive one. It demonstrates that US institutional investors are now starting to share the confidence that retail investors have demonstrated over recent months. The future of the company seems bright and we shareholders seem set to benefit.

    Disclosure: I am long BNIKF.

    Additional disclosure: These are the opinions of the author and do not represent investment advice.

    Themes: Benitec, biotech, shrna, rnai, Arrowhead Stocks: BNIKF, ARWR
Back To Pannobhaso's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (2)
Track new comments
  • GreenGrowthGeek
    , contributor
    Comments (736) | Send Message
     
    Great article again P. I'm frankly shocked that shares in Australia just closed up over 16% after a major dilution. Hence, your thesis looks sound. Most stocks drop, at least for a couple days after dilutions even if the fund raising can be seen as a long term positive. Benitec has serious legs. It seems unbelievable, but the share price could definitely be approaching $20 in the next 12 months.
    24 Feb, 12:40 AM Reply Like
  • subrkaus3
    , contributor
    Comments (81) | Send Message
     
    Once again good article Pannobhaso. Long BNIKF!
    24 Feb, 11:55 AM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Most Commented
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.